Loading... (0%)
About liver disease

Press releases

GENFIT: Positive Outcome from the 18-month Pre-Planned Safety Review by the DSMB, in RESOLVE-IT Phase 3 Clinical Trial with Elafibranor
Published on: 11/22/2017
GENFIT completes a €180 million offering of bonds convertible into new shares and/or exchangeable for existing shares (“OCEANEs”) due 2022
Published on: 10/17/2017
GENFIT announces the success of its offering of bonds convertible into new shares and/or exchangeable for existing shares (“OCEANEs”) due 2022 for an amount of €180 million
Published on: 10/11/2017
GENFIT launches an offering of bonds convertible into new shares and/or exchangeable for existing shares (“OCEANEs”) due 2022 for an amount of approximately €150 million
Published on: 10/11/2017
GENFIT: Third quarter 2017 financial information
Published on: 10/11/2017
GENFIT announces its participation at the 2017 AASLD Meeting
Published on: 10/02/2017
2017 Half-Year Results: Cash Position at End of Period at €126M and Significant Advances in the Company’s Pipeline
Published on: 09/25/2017
Corporate presentation
  • Analyst/Investor presentation
    October 2017
Documentation
  • NAFLD/NASH Medical Monograph
    English